EHA 2023: Janssen’s talquetamab shows promise in multiple myeloma

cafead

Administrator
Staff member
  • cafead   Jun 13, 2023 at 10:42: AM
via Talquetamab offers a distinct competitive advantage with its innovative mode of action, enabling the treatment of patients resistant to anti-B cell maturation antigen (BCMA) therapeutics.

article source
 

<